Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...PharmaLedger
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...PharmaLedger
In this presentation, you will find:
An introduction to the PharmaLedger project presented by Maria Eugenia (Xenia) Beltran | Project Coordinator / DRA and Use Case co-lead (Universidad Politécnica de Madrid)
Topic 1 | Clinical Trial eRecruitment | Despina Daliani (Onorach) and Ken Nessel (Pfizer)
Topic 2 | Clinical Trial eConsent | Hernando C. Giraldo (Boehringer Ingelheim) and Despina Daliani (Onorach)
Topic 3 | Health Data IoT Medical Device | Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
Topic 4 | Health Data Personalised Medicine | Beatriz Merino (Universidad Politécnica de Madrid) and Christos Kontogiorgis (Democritus University of Thrace)
You can also learn more about our #2 Open Webinar on Clinical Trials & Health Data by rewatching our video recording including the Q&A by clicking on the button below:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Lateral flow assays are the most robust, mature immuno sensor available today. Performance in some applications has historically been limited by difficulties in multiplexing and quantification. Novel approaches have been developed and commercialized in recent years that allow for the development and manufacturing of highly multiplexed arrays in lateral flow assays. The patented Symbolics (tm) approach is one such methodology. Symboics (tm) allows for the creation of arrays in lateral flow fields that develop evenly, allowing in turn for the creation of highly complex features such as letters and symbols and also allows for creation of multiplex assays with advanced features such as internal controls. This presentation introduces the principles of multiplexed arraying and the Symbolics technology
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...PharmaLedger
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...PharmaLedger
In this presentation, you will find:
An introduction to the PharmaLedger project presented by Maria Eugenia (Xenia) Beltran | Project Coordinator / DRA and Use Case co-lead (Universidad Politécnica de Madrid)
Topic 1 | Clinical Trial eRecruitment | Despina Daliani (Onorach) and Ken Nessel (Pfizer)
Topic 2 | Clinical Trial eConsent | Hernando C. Giraldo (Boehringer Ingelheim) and Despina Daliani (Onorach)
Topic 3 | Health Data IoT Medical Device | Disa Lee Choun (UCB) and Francesca Rocchi (Bambino Gesù Children Hospital)
Topic 4 | Health Data Personalised Medicine | Beatriz Merino (Universidad Politécnica de Madrid) and Christos Kontogiorgis (Democritus University of Thrace)
You can also learn more about our #2 Open Webinar on Clinical Trials & Health Data by rewatching our video recording including the Q&A by clicking on the button below:
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
The American Association of Clinical Chemistry was held this year in Atlanta, GA. Kalorama was at the meeting and notes several developments, with a particular focus on point-of-care.
A smart enteral feeding system with integrated reflux monitoring and prevention. The system comprises of both proprietary hardware and software. A
feeding tube (LifeSafe Tube™) with embedded sensors collects data continuously. Proprietary algorithms analyze the collected data, weighing multiple risk factors such as patient position and physiological functions (ie: sneezing, coughing) to predict when reflux will occur. This information is used to automatically calibrate a feeding pump and optimize feeding rate in order to prevent reflux.
Powerful Medical Branding for Your Medical Device Investor Deck. Example: Amnis Therapeutics Investor Deck by Berliner Design (www.berlinerdesign.co.il).
Miniature Drug delivery System uses micro-fabricated devices to administer drugs to the host and has advantages over a conventional drug delivery system
A MEMS based Implantable Drug Delivery System (IDDS) is discussed. The heart of the system is an in-plane MEMS micropumps enables us to make a compact, inexpensive system. A conceptual IDDS design is proposed. This design consists of an implantable unit which houses the micropumps, electronic and power circuitry. This implantable unit is connected to a subcutaneous port via a silicone catheter. The subcutaneous port acts as a refillable reservoir. This leads to a reduction in unit volume and makes the system customizable. The IDDS pumps drug into surrounding tissue with the help of a MEMS based micropumps. Similarly Microneedles are also used in drug administration.
This report gives an overview of patenting activity around Miniature Drug Delivery System. Smart drug delivery system is used for delivering drugs to the host effectively and improves the quality of life of the patients. Patents were categorized as per key Drug Delivery administration methods, types of sensors, applications, communication techniques and analyzed for generating different trends with Patent iNSIGHT Pro.
Miniature Drug Delivery System technology has seen a consistent increase in the number of patent publications from 2008 till 2012 as the need for smart drug delivery has increase globally.
Published: Apr 30, 2013
10 Most Innovative CRO’s To Watch In 2022.pdfinsightscare
During the COVID-19 pandemic, if clinicians, healthcare service-providing staff, nurses, and doctors were battling at the forefront, then the Clinical Research Organizations (CROs) have been working hard
Powering the Future of Healthcare in Asia - ETPL "IOT FOR HEALTH" PROGRAM | T...Julien de Salaberry
Presentation on the importance and impact of IoT Healthcare / Healthtech on the delivery of healthcare in Asia to the ETPL "IOT FOR HEALTH" PROGRAM cohort
#healthtechasia
medical disposables -gloves,nonwovens,plastic disposables and sterilization p...倩倩 郭
There are disposable gloves,nonwoven disposables,plastic disposables and sterilization pouches in intco medical.
Contact:Lynette Guo
Email:lynetteguo@intco,com,cn
Phone:+86-34978818-1118
Disruptive technology from Anteo Technologies for Lateral Flow testing. New product launching at AACC Conference July 2016. Five times improvement in sensitivity
Discussing advances in Magnetic Bead coating technologies - Page 9 & 10 - Article from Joshua Soldo from Australian listed Biotech company Anteo Diagnostics ASX:ADO
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Anteo Diagnostics & Atomo Troponin Lateral Flow test
1. Anteo Diagnostics Limited ACN 070 028 625
Unit 4, 26 Brandl St, Eight Mile Plains, QLD 4113, Australia
p: +61 7 3219 0085 f: +61 7 3219 0553
contact@anteodx.com www.anteodx.com
15 June 2016
Funding For New Rapid Blood Test To Help Detect Heart Attacks: Atomo
Partners with Anteo
Anteo is pleased to announce that it will partner with Sydney-based Atomo Diagnostics to
develop a clinical prototype of a cost effective and accurate point of care test for the
diagnosis of heart attacks.
Australian medical device innovator, Atomo Diagnostics today announced it has been
selected as a winner of the Advance Queensland Johnson & Johnson Innovation QuickFire
Challenge. The win was announced by the Premier of Queensland, Annastacia Palaszczuk,
at the QUT Institute of Health & Biomedical Innovation.
Atomo received the award in the medical device sector of the challenge, which comes with
$100,000 in funding to deliver a ‘proof of concept’ program for an innovative rapid test to
detect heart attack.
Atomo Diagnostics Group CEO John Kelly said, "We gratefully thank the Queensland
Government and Johnson & Johnson Innovation for their support. This funding will allow us
to evaluate the feasibility of an easy-to-use test for the early detection of heart attacks away
from laboratory and hospital settings.”
Anteo will develop a rapid test strip for cardiac troponin using its coating technology which
has been previously shown to improve the performance of immunoassay tests. Atomo will
then integrate this into its award-winning AtomoRapid platform which provides unparalleled
ease of use and robustness in point of care settings.
Anteo Group CEO Jef Vangenechten said, “Anteo’s novel binding chemistry is particularly
well suited to advancing performance improvements of point of care tests. We are pleased to
partner with a fellow innovator of the Australian medical device sector, to develop a next
generation troponin test on the AtomoRapid platform.”
The troponin test market is one of the largest and fastest growing single cardiac biomarkers
segments1
and the point of care (non-laboratory) market is estimated to be $350 million per
annum2
. Subject to a successful proof of concept phase, Atomo and Anteo will consider
options to fully commercialise an AtomoRapid based troponin solution for the cardiac market.
1
Cardiac Marker Diagnostic Testing Markets, TriMark Publications, Volume: TMRCMARK15-0701, July 2015
2
Trinity Biotech Announces European Approval of Guideline Compliant, Point-of-Care, High Sensitivity Troponin I
Product, accessed November 2015
2. Anteo Diagnostics Limited ACN 070 028 625
Unit 4, 26 Brandl St, Eight Mile Plains, QLD 4113, Australia
p: +61 7 3219 0085 f: +61 7 3219 0553
contact@anteodx.com www.anteodx.com
For more information, please contact:
Olya Savvina Tim Allerton or Andrew Geddes
Anteo CityPR
Tel: +61 (7) 3219 0085 Tel: +61 (2) 9267 4511
About Anteo Diagnostics
Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and
commercialising products for sale into the life sciences, in-vitro diagnostics, point of care,
medical devices and bioseparations markets.
The Anteo group owns a patented nano coating technology, which is used by healthcare
customers as an addition to their existing tests, to consistently enable laboratory test results
that can either be delivered faster, cheaper, or with greater specificity or sensitivity than
incumbent tests.
This nano coating technology, called Mix&Go for healthcare markets, is starting to gain
traction with the Company’s target markets, due to its ability to revolutionise the way
scientists work.
While Anteo is largely focused on the healthcare markets, the nano coating technology also
has potential for use in other areas, such as batteries. Early stage research is being
conducted into the viability of this battery product.
For more information, please visit www.anteodx.com
About Atomo Diagnostics
Atomo Diagnostics is commercialising a range of innovative and easy to use rapid diagnostic
solutions that deliver clinical and economic value to healthcare consumers and providers
globally. The company was established to create healthcare products that improve levels of
convenience, simplicity and user experience. Atomo Diagnostics is based in Sydney,
Australia, with corporate offices in South Africa and the UK. The company is led by an
experienced team with track records of success commercialising healthcare products that
transform and improve clinical outcomes for a range of unmet medical needs.
For more information, please visit www.atomodiagnostics.com